Center of Experimental Orthopaedics, Saarland University and Saarland University Medical Center, D-66421, Homburg/Saar, Germany.
Departments of Anesthesia and Surgery, Children's Hospital Boston, Harvard Medical School, Boston, MA, 02115, USA.
Adv Mater. 2021 Apr;33(16):e2008451. doi: 10.1002/adma.202008451. Epub 2021 Mar 18.
The regeneration of focal articular cartilage defects is complicated by the reduced quality of the repair tissue and the potential development of perifocal osteoarthritis (OA). Biomaterial-guided gene therapy may enhance cartilage repair by controlling the release of therapeutic sequences in a spatiotemporal manner. Here, the benefits of delivering a recombinant adeno-associated virus (rAAV) vector coding for the human insulin-like growth factor I (IGF-I) via an alginate hydrogel (IGF-I/AlgPH155) to enhance repair of full-thickness chondral defects following microfracture surgery after one year in minipigs versus control (lacZ/AlgPH155) treatment are reported. Sustained IGF-I overexpression is significantly achieved in the repair tissue of defects treated with IGF-I/AlgPH155 versus those receiving lacZ/AlgPH155 for one year and in the cartilage surrounding the defects. Administration of IGF-I/AlgPH155 significantly improves parameters of cartilage repair at one year relative to lacZ/AlgPH155 (semiquantitative total histological score, cell densities, matrix deposition) without deleterious or immune reactions. Remarkably, delivery of IGF-I/AlgPH155 also significantly reduces perifocal OA and inflammation after one year versus lacZ/AlgPH155 treatment. Biomaterial-guided rAAV gene transfer represents a valuable clinical approach to promote cartilage repair and to protect against OA.
关节内软骨缺损的再生很复杂,修复组织的质量降低,且易发生周边骨关节炎(OA)。生物材料引导的基因治疗可通过时空控制治疗序列的释放来增强软骨修复。本研究旨在探讨通过海藻酸钠水凝胶(IGF-I/AlgPH155)递送编码人胰岛素样生长因子 I(IGF-I)的重组腺相关病毒(rAAV)载体,能否在猪的全层软骨缺损模型中增强微骨折术后一年的修复效果,与对照组(lacZ/AlgPH155)相比,rAAV 基因治疗是否有优势。结果发现,IGF-I/AlgPH155 治疗组的修复组织中 IGF-I 持续过表达,持续时间为一年,而 lacZ/AlgPH155 组则无。IGF-I/AlgPH155 治疗组的软骨周围也观察到 IGF-I 过表达。与 lacZ/AlgPH155 相比,IGF-I/AlgPH155 治疗组在一年时的软骨修复参数显著改善(半定量总组织学评分、细胞密度、基质沉积),且无不良反应或免疫反应。值得注意的是,IGF-I/AlgPH155 治疗还能显著降低周边 OA 和炎症。生物材料引导的 rAAV 基因转移为促进软骨修复和预防 OA 提供了一种有价值的临床方法。